Lotivibart vs Zinlirvimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
Lotivibart
Developed by ViiV Healthcare
NCT04871113 · Phase 2 · completed
Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.
Next expected readout: January 2027 · NCT07053384 (registry estimate)
Reported efficacy
Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Adverse Events (AEs) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Worst-case Maximum Grade 2-4 Increase in Post-baseline Values of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Compared to the Baseline Values - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase); Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Findings - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase); Number of Participants With Grade 2-4 Injection Site Reactions (ISR) - Monotherapy Phase (Up to Day 84 or end of Monotherapy Phase): Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69) (not_applicable)
Result source: NCT04871113
Zinlirvimab
Developed by Gilead Sciences under a licence from The Rockefeller University
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT07054931 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lotivibart | Zinlirvimab |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Trial running · NCT07683000 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Trial running · NCT07683000 |
| CD4 count, change (week 48) | —Not reported | —Trial running · NCT07683000 |
HIV-1 RNA below 50 copies/mL (week 48)
- Lotivibart
- —Not reported
- Zinlirvimab
- —Trial running · NCT07683000
HIV-1 RNA 50 copies/mL or more (week 48)
- Lotivibart
- —Not reported
- Zinlirvimab
- —Trial running · NCT07683000
CD4 count, change (week 48)
- Lotivibart
- —Not reported
- Zinlirvimab
- —Trial running · NCT07683000
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zinlirvimab: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lotivibart: 3 of 4 rows · Zinlirvimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lotivibart |
|---|---|
| Dropout rate | —700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results—700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 12.5%3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination 0%60 mg/kg NCT05291520 · Phase 1 · monotherapy 0%20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Discontinued due to AEs | —700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results—700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 —40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 —3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination —60 mg/kg NCT05291520 · Phase 1 · monotherapy —20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Serious AEs | 0%700 mg IVa NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results0%700 mg SC NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 18.8%700 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 25%700 mg SC NCT04871113 · Phase 2 · combination · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 0%280 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%70 mg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 12.5%70 mg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%40 mg/kg IV NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 12.5%40 mg/kg IV NCT04871113 · Phase 2 · combination · HIV · phase 2 0%3000 mg + rHuPH20 NCT05291520 · Phase 1 · combination 0%60 mg/kg NCT05291520 · Phase 1 · monotherapy 0%20 mg/kg + rHuPH20 NCT05291520 · Phase 1 · combination |
| Most frequent reported AEs | 700 mg IVa influenza 12.5% rhinitis 12.5% aspartate aminotransferase increased 6.3% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 show 12 more results700 mg SC headache 18.8% blood creatine phosphokinase increased 12.5% neutropenia 12.5% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 700 mg IV upper respiratory tract infection 18.8% anaemia 12.5% anogenital warts 6.3% NCT04871113 · Phase 2 · combination · HIV · phase 2 700 mg SC neutropenia 12.5% pharyngitis 12.5% tonsillitis 12.5% NCT04871113 · Phase 2 · combination · HIV · phase 2 280 mg IV abdominal pain 16.7% asthenia 16.7% bronchitis 16.7% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 280 mg IV depression 16.7% hypertension 16.7% influenza like illness 16.7% NCT04871113 · Phase 2 · combination · HIV · phase 2 70 mg IV covid-19 12.5% alanine aminotransferase increased 6.3% anal abscess 6.3% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 70 mg IV upper respiratory tract infection 12.5% vomiting 12.5% abdominal pain 6.3% NCT04871113 · Phase 2 · combination · HIV · phase 2 40 mg/kg IV abdominal pain 12.5% blood creatine phosphokinase increased 12.5% covid-19 12.5% NCT04871113 · Phase 2 · monotherapy · HIV · phase 2 40 mg/kg IV covid-19 25% proctitis gonococcal 25% syphilis 25% NCT04871113 · Phase 2 · combination · HIV · phase 2 3000 mg + rHuPH20 injection site erythema 100% injection site bruising 25% injection site pain 25% NCT05291520 · Phase 1 · combination 60 mg/kg medical device site dermatitis 12.5% muscle tightness 12.5% covid-19 0% NCT05291520 · Phase 1 · monotherapy 20 mg/kg + rHuPH20 injection site erythema 87.5% upper respiratory tract infection 25% headache 12.5% NCT05291520 · Phase 1 · combination |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lotivibart
show 4 more results
show 4 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lotivibart's landscape · Zinlirvimab's landscape